Nationwide registry- based analysis of cardiovascular risk factors and adverse outcomes in patients treated with stronium ranelate
In conclusion, baseline cardiovascular diseases are common in patients treated with strontium ranelate, with more than half of strontium ranelate users being current users of antiplatelet drugs or having a history of cerebrovascular disease, peripheral … Leer más











